Zeta,
rkrw and Rick both decided Aquavan would be a hard sell even if approved. Meanwhile, I don't like the Aggrastat purchase. Some felt that a more interested sales force could do something for it, because Merck had "neglected" it. Well, IMO, there are reasons Merck neglected it. I take it you're registered for Medscape (if not, it's free):
medscape.com
In a nutshell, Aggrastat loses on efficacy and overall cost effectiveness to Integrilin and ReoPro. I think it'll be tough sell, too. With the Gliadel wafers making a minimal impact (sadly), I see nothing in GLFD's product line-up or pipe that looks compelling. I used to think of them as a well managed company, even if their development ambitions hadn't yet played out. With the Aggrastat buy, that concept was shaken. One of the reasons I used to like them is that I thought their CFO was sharp, that they had managed their finances especially well. His departure is another red flag.
I've watched for a long time, traded once or twice. But I never have and probably never will actually invest in this one.
Cheers, Tuck |
